PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Escitalopram Oxalate→

Escitalopram Oxalate PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
219861-08-2
Molecular formula
C22H23FN2O5
Molecular weight
414.4 g/mol
Drug class
Selective serotonin reuptake inhibitor (SSRI)antidepressant
Mechanism of action
Selectively inhibits the serotonin transporter (SERT), reducing neuronal reuptake of serotonin and increasing serotonergic neurotransmission. Escitalopram is the S-enantiomer of citalopram; oxalate is a counter-ion in some products.
Indications / reported uses
  • Treatment of major depressive disorder in adults and adolescents where authorised
  • Treatment of generalised anxiety disorder in adults under the US product indication; other anxiety indications vary by jurisdiction

Sources: US DailyMed — Escitalopram products · NHS — Escitalopram

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Escitalopram Oxalate PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Escitalopram Oxalate Permitted Daily Exposure (PDE) report (the Escitalopram Oxalate PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Escitalopram Oxalate Occupational Exposure Limit (OEL) report (the Escitalopram Oxalate OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.